Dyne Therapeutics Expands Debt Facility to $400M, Securing $50M Immediately
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics expanded its non-dilutive senior secured term loan facility with Hercules Capital to a total of up to $400 million. The company received $50 million immediately, with an additional $50 million available upon achieving certain milestones and a further $75 million at Hercules' discretion. This financing significantly strengthens Dyne's balance sheet and provides crucial financial flexibility as it advances its lead candidates, z-rostudirsen and z-basivarsen, through critical clinical and regulatory milestones towards potential U.S. launches within the next two years. This follows recent positive clinical updates, including a BLA submission and full trial enrollment, and provides a non-dilutive funding source after shareholders approved a significant increase in authorized common stock.
At the time of this announcement, DYN was trading at $18.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.06 to $25.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.